Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

An immunotherapy treatment has been found to ‘change the world’ for head and neck cancer patients by giving them an extra two and a half years before the disease worsens or comes back. During a major ...

Patients with head and neck cancer face financial burdens due to inadequate insurance coverage for post-treatment dental care. 79% of surveyed patients were advised to undergo dental screening, but ...

Adding neoadjuvant and adjuvant pembrolizumab to the standard of care significantly improved event-free survival in patients with previously untreated, locally advanced head and neck squamous cell ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Nivolumab plus ipilimumab or relatlimab nearly doubled response rates compared to nivolumab alone in head and neck cancer. Patients with major pathologic responses had better disease-free and overall ...